Signifikanter Überlebensvorteil durch Sacituzumab-Govitecan beim TNBC
Crossref DOI link: https://doi.org/10.1007/s15004-021-8782-8
Published Online: 2021-09-22
Published Print: 2021-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Weiße, Sebastian
Quaester, Svenja
Dunst, Jürgen
Text and Data Mining valid from 2021-09-01
Version of Record valid from 2021-09-01
Article History
First Online: 22 September 2021